SwedenBIO has started a new mapping of Sweden’s pharmaceutical pipeline to follow its development and strengthen the visibility of Swedish pharmaceutical innovation in the global arena.

The last Swedish Drug Discovery and Development Pipeline-report was released in March 2023 and gave a detailed picture of 506 pharmaceutical projects in Swedish companies. Now it’s time to update the analysis and see how the pipeline has evolved.

“The purpose is to map Swedish pharmaceutical development in order to make it visible to international investors and decision-makers in politics, business and academia, states Maja Neiman, Scientific Director, SwedenBIO. “It primarily aims to promote Sweden’s global position in pharmaceutical development, but also to show examples of which successes are consistent with Sweden’s motley ecosystem for life science.”

SwedenBIO: How does the Swedish drug development pipeline compare internationally, and which factors contribute to Sweden’s position in the global life science arena?

“The Swedish drug development pipeline is robust and competitive on the international stage. In the previous Pipeline report that came out in 2023, there were 159 companies actively developing new drugs and a total of 506 projects. Sweden’s combined pipeline is comparable to that of a large global pharmaceutical company. Factors that contribute to Sweden’s strong position include a high level of innovation, significant investments in research and development, and a strong ecosystem that supports the life science industry,” says Neiman.

SwedenBIO: In what ways does the report help market Swedish pharmaceutical research?

“It functions as a tool to show the strength and potential of Swedish pharmaceutical research to a global audience. By providing detailed insights into ongoing projects, the therapeutic areas being explored and the breakdown of research projects into clinical phases, the report highlights Sweden’s capabilities and innovations. This information is crucial for attracting international investment, promoting collaborations and positioning Sweden as a leading actor,” says Neiman.

Source: SwedenBIO